{"id":"https://openalex.org/W2046516625","doi":"https://doi.org/10.1097/cad.0b013e32830f9046","title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","display_name":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","publication_year":2008,"publication_date":"2008-08-28","ids":{"openalex":"https://openalex.org/W2046516625","doi":"https://doi.org/10.1097/cad.0b013e32830f9046","mag":"2046516625","pmid":"https://pubmed.ncbi.nlm.nih.gov/18766004"},"language":"en","primary_location":{"id":"doi:10.1097/cad.0b013e32830f9046","doi":"https://doi.org/10.1097/cad.0b013e32830f9046","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0b013e32830f9046","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2046516625"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112516025","display_name":"Neil P. Desai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166201","display_name":"Abraxis (United States)","ror":"https://ror.org/05r1gew95","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166201"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Neil P. Desai","raw_affiliation_strings":["Abraxis BioScience, LLC, Los Angeles, California 90025-1506, USA. ndesai@abraxisbio.com","Abraxis BioScience, LLC, Los Angeles, California","to Neil P. Desai, Abraxis BioScience, LLC, 11755 Wilshire Blvd., Suite #2000, Los Angeles, CA 90025-1506, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abraxis BioScience, LLC, Los Angeles, California 90025-1506, USA. ndesai@abraxisbio.com","institution_ids":["https://openalex.org/I4210166201"]},{"raw_affiliation_string":"Abraxis BioScience, LLC, Los Angeles, California","institution_ids":["https://openalex.org/I4210166201"]},{"raw_affiliation_string":"to Neil P. Desai, Abraxis BioScience, LLC, 11755 Wilshire Blvd., Suite #2000, Los Angeles, CA 90025-1506, USA","institution_ids":["https://openalex.org/I4210166201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059615305","display_name":"Vuong N. Trieu","orcid":"https://orcid.org/0000-0002-6675-0811","observed_orcids":["https://orcid.org/0000-0002-6675-0811"]},"institutions":[{"id":"https://openalex.org/I4210166201","display_name":"Abraxis (United States)","ror":"https://ror.org/05r1gew95","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vuong Trieu","raw_affiliation_strings":["Abraxis BioScience, LLC, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abraxis BioScience, LLC, Los Angeles, California","institution_ids":["https://openalex.org/I4210166201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110557250","display_name":"Larn Hwang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166201","display_name":"Abraxis (United States)","ror":"https://ror.org/05r1gew95","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Larn Yuan Hwang","raw_affiliation_strings":["Abraxis BioScience, LLC, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abraxis BioScience, LLC, Los Angeles, California","institution_ids":["https://openalex.org/I4210166201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078940530","display_name":"Wu Rujin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166201","display_name":"Abraxis (United States)","ror":"https://ror.org/05r1gew95","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rujin Wu","raw_affiliation_strings":["Abraxis BioScience, LLC, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abraxis BioScience, LLC, Los Angeles, California","institution_ids":["https://openalex.org/I4210166201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087962211","display_name":"Patrick Soon\u2010Shiong","orcid":"https://orcid.org/0000-0002-4682-8298","observed_orcids":["https://orcid.org/0000-0002-4682-8298"]},"institutions":[{"id":"https://openalex.org/I4210166201","display_name":"Abraxis (United States)","ror":"https://ror.org/05r1gew95","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Soon-Shiong","raw_affiliation_strings":["Abraxis BioScience, LLC, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abraxis BioScience, LLC, Los Angeles, California","institution_ids":["https://openalex.org/I4210166201"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085028425","display_name":"William John Gradishar","orcid":"https://orcid.org/0000-0002-2772-3140","observed_orcids":["https://orcid.org/0000-0002-2772-3140"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William J. Gradishar","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5112516025"],"corresponding_institution_ids":["https://openalex.org/I4210166201"],"apc_list":null,"apc_paid":null,"fwci":4.1086,"has_fulltext":false,"cited_by_count":212,"citation_normalized_percentile":{"value":0.94819578,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"19","issue":"9","first_page":"899","last_page":"909"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.7749000191688538,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.7749000191688538,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.17000000178813934,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.04149999842047691,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9010000228881836},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.6520000100135803},{"id":"https://openalex.org/keywords/sparc","display_name":"SPARC","score":0.9980000257492065},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8100000023841858},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.7369999885559082},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.8009999990463257},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5049999952316284},{"id":"https://openalex.org/keywords/albumin-binding","display_name":"albumin binding","score":0.4399999976158142},{"id":"https://openalex.org/keywords/gp60","display_name":"gp60 gene","score":0.7310000061988831},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.6439999938011169},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.621999979019165},{"id":"https://openalex.org/keywords/mda-mb-231-cells","display_name":"MDA-MB-231 cells","score":0.746999979019165}],"concepts":[{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.9132019877433777},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.9002654552459717},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.4941754639148712},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48837655782699585},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.45143041014671326},{"id":"https://openalex.org/C2776125364","wikidata":"https://www.wikidata.org/wiki/Q169219","display_name":"Albumin","level":2,"score":0.437654972076416},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.43383997678756714},{"id":"https://openalex.org/C2776872082","wikidata":"https://www.wikidata.org/wiki/Q181874","display_name":"HER2/neu","level":4,"score":0.4177051782608032},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.4161757528781891},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3812224864959717},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3774230480194092},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.35792994499206543},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3014397621154785},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2986048460006714}],"mesh":[{"descriptor_ui":"D000068196","descriptor_name":"Albumin-Bound Paclitaxel","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077143","descriptor_name":"Docetaxel","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011136","descriptor_name":"Polysorbates","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015676","descriptor_name":"Osteonectin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043823","descriptor_name":"Taxoids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D043823","descriptor_name":"Taxoids","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/cad.0b013e32830f9046","doi":"https://doi.org/10.1097/cad.0b013e32830f9046","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0b013e32830f9046","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:18766004","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18766004","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320330412","display_name":"Scheme for Promotion of Academic and Research Collaboration","ror":null}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W11467293","https://openalex.org/W1583373908","https://openalex.org/W1849061857","https://openalex.org/W1865619950","https://openalex.org/W1881209172","https://openalex.org/W1885306047","https://openalex.org/W1935541780","https://openalex.org/W1967647822","https://openalex.org/W1969982587","https://openalex.org/W1981667569","https://openalex.org/W2024554279","https://openalex.org/W2031125940","https://openalex.org/W2033957216","https://openalex.org/W2039578335","https://openalex.org/W2043905676","https://openalex.org/W2047737749","https://openalex.org/W2055679227","https://openalex.org/W2075098308","https://openalex.org/W2081406767","https://openalex.org/W2086786188","https://openalex.org/W2088766801","https://openalex.org/W2090280374","https://openalex.org/W2101100140","https://openalex.org/W2111970355","https://openalex.org/W2121125632","https://openalex.org/W2128941584","https://openalex.org/W2129380686","https://openalex.org/W2132448724","https://openalex.org/W2144536924","https://openalex.org/W2150333976","https://openalex.org/W2153017356","https://openalex.org/W2184694295","https://openalex.org/W2415206373","https://openalex.org/W6677002573"],"related_works":["https://openalex.org/W2056782701","https://openalex.org/W3000098631","https://openalex.org/W4323308916","https://openalex.org/W2012515540","https://openalex.org/W2044202701","https://openalex.org/W29090612","https://openalex.org/W2087862302","https://openalex.org/W2094011365","https://openalex.org/W2171435320","https://openalex.org/W4206250006"],"abstract_inverted_index":{"Nanoparticle":[0],"albumin-bound":[1,6],"(nab)-paclitaxel":[2],"(Abraxane)":[3],"is":[4],"an":[5],"130-nm":[7],"particle":[8],"form":[9],"of":[10,66,89,99,254,267,276],"paclitaxel":[11,23],"that":[12,250],"demonstrated":[13,249],"higher":[14,258],"efficacy":[15,98,253],"and":[16,25,41,45,56,91,129,132,143,151,157,164,168,171,178,236,269,279],"was":[17,187,219,256],"well":[18],"tolerated":[19],"compared":[20,101,259],"with":[21,48,81,102,115,210,229,243,260,273],"solvent-based":[22],"(Taxol)":[24],"docetaxel":[26,153,193,226,262],"(Taxotere)":[27],"in":[28,58,60,73,94,180,198,227,240,263,270,286],"clinical":[29],"trials":[30],"for":[31,123,290],"metastatic":[32],"breast":[33,74,170],"cancer.":[34],"Nab-paclitaxel":[35,183],"enhances":[36],"tumor":[37,62,111],"targeting":[38],"through":[39],"gp60":[40],"caveolae-mediated":[42],"endothelial":[43],"transcytosis":[44],"the":[46,49,61,87,96,251],"association":[47],"albumin-binding":[50],"protein":[51],"SPARC":[52,92,158,181,208,233,245,280],"(secreted":[53],"protein,":[54],"acidic":[55],"rich":[57],"cysteine)":[59],"microenvironment.":[63],"The":[64,203],"overexpression":[65],"human":[67,110],"epidermal":[68],"growth":[69],"factor":[70],"receptor-2":[71],"(HER2)":[72],"cancer":[75],"has":[76],"been":[77],"shown":[78],"to":[79,83,221,231],"correlate":[80],"resistance":[82],"paclitaxel.":[84],"To":[85],"evaluate":[86],"importance":[88],"HER2":[90,156,176,278],"status":[93,159],"determining":[95,287],"relative":[97,252],"nab-paclitaxel":[100,116,218,255],"polysorbate-based":[103,152,192,225,261],"docetaxel,":[104],"nude":[105],"mice":[106],"bearing":[107],"six":[108],"different":[109],"xenografts":[112],"were":[113,160,175],"treated":[114],"(MX-1:":[117],"15":[118],"mg/kg,":[119,134,145],"once":[120],"a":[121],"week":[122],"3":[124],"weeks;":[125],"LX-1,":[126],"MDA-MB-231/HER2+,":[127],"PC3,":[128],"HT29:":[130],"50":[131],"120":[133,142],"every":[135,146],"4":[136,147],"days":[137,148],"three":[138,149,200],"times":[139],";":[140],"MDA-MB-231:":[141],"180":[144],"times)":[150],"(15":[154],"mg/kg).":[155],"analyzed":[161],"by":[162],"RT-PCR":[163],"immunohistochemical":[165],"staining.":[166],"MDA-MB-231":[167],"MX-1":[169],"LX-1":[172],"lung":[173],"cancers":[174],"negative":[177],"low":[179,244],"expression.":[182,246],"at":[184,194],"submaximum-tolerated":[185],"dosage":[186,197],"significantly":[188,257],"more":[189],"effective":[190],"than":[191,224],"its":[195],"maximum-tolerated":[196],"these":[199,215],"HER2-negative":[201,264],"tumors.":[202],"HER2-positive":[204,216,271],"tumors":[205,228,242,265,272],"had":[206],"variable":[207],"expression,":[209],"MDA-MB-231/HER2+":[211,241],"<PC3":[212],"<HT29.":[213],"In":[214],"tumors,":[217],"equal":[220],"or":[222],"better":[223],"medium":[230],"high":[232,274],"levels":[234,275],"(PC3":[235],"HT29),":[237],"but":[238],"not":[239],"These":[247],"results":[248],"(three":[266],"three)":[268],"SPARC.":[277],"expression":[281],"may":[282],"be":[283],"useful":[284],"biomarkers":[285],"antitumor":[288],"effectiveness":[289],"taxanes.":[291]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":11},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":17},{"year":2016,"cited_by_count":15},{"year":2015,"cited_by_count":16},{"year":2014,"cited_by_count":18},{"year":2013,"cited_by_count":25},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}